Options: Show MedDRA Preferred Terms
Side effect | Data for drug | Placebo | Labels | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||
Agranulocytosis | x | x | x | x | x | |||||||
Aplastic anaemia | x | x | x | x | x | |||||||
Blister | x | |||||||||||
Oedema | x | |||||||||||
Toxic epidermal necrolysis | x | x | x | x | x | |||||||
Blood disorder | x | x | x | x | x | |||||||
Hypersensitivity | x | x | x | x | x | x | x | x | x | |||
Systemic lupus erythematosus | x | x | x | |||||||||
Pruritus | x | |||||||||||
Stevens-Johnson syndrome | x | x | x | x | x | x | x | x | x | |||
Erythema | x | |||||||||||
Hepatic necrosis | x | x | x | x | x | |||||||
Fatal outcomes | x | x | x | |||||||||
Conjunctival irritation | x | |||||||||||
Lupus erythematosus | x | |||||||||||
Secondary infection | x | x | x | x | x | |||||||
Stinging | x | x | x | x | x | x | x | |||||
Conjunctival hyperaemia | x | x | x | x | x |
Information about indications was extracted from the indications and usage sections of the labels.
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |